Clinical Trial

AAV2-hAADC for Parkinson's Disease (PDCS-01)

Study acronym: PDCS-01
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic code for an enzyme called Aromatic L-Amino Acid Decarboxylase, or AADC for short. In this study, AAV2-hAADC is delivered to two parts of the brain called the putamen and the caudate. Increasing the amount of AADC gene in these parts of the brain converts more levodopa into dopamine, the chemical that is lacking in PD.
Trial Details
NCT Number NCT07267065
Lead Sponsor Krzysztof Bankiewicz
Conditions Parkinson's Disease (PD), Early Onset Parkinson Disease
Enrollment 9 participants
Start Date 2026-02-01
Primary Completion 2028-08-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05